Get the Stockscreener App
0.5304
2.63%
-0.037
Matinas Biopharma Holdings Inc stock is traded at $0.5304, with a volume of 126.97K.
It is down -2.63% in the last 24 hours and down -81.61% over the past month.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.
See More
Previous Close:
$0.5674
Open:
$0.56
24h Volume:
126.97K
Relative Volume:
0.20
Market Cap:
$2.85M
Revenue:
-
Net Income/Loss:
$-22.94M
P/E Ratio:
-4.8218
EPS:
-0.11
Net Cash Flow:
$-15.50M
1W Performance:
-80.20%
1M Performance:
-81.61%
6M Performance:
+215.89%
1Y Performance:
+140.22%
1-Day Range:
$0.52
$0.5678
1-Week Range:
$0.5052
$2.85
52-Week Range:
$0.09
$4.49
Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile
Name
Matinas Biopharma Holdings Inc
Sector
Industry
Phone
908-443-1860
Address
1545 Route 206 South, Suite 302, Bedminster, NJ
Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-26-20 | Resumed | Piper Sandler | Overweight |
| Jan-27-20 | Initiated | Piper Sandler | Overweight |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Jan-09-20 | Initiated | Aegis Capital | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Matinas Biopharma Holdings Inc Stock (MTNB) Latest News
Maxim Group Reiterates Hold Rating for Matinas BioPharma (NYSEAMERICAN:MTNB) - Defense World
MTNBMatinas BioPharma Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Matinas BioPharma plunges as deal for lead asset falls apart - MSN
Matinas BioPharma mulls wind-down as antifungal therapy deal falls through - Pharmaceutical Technology
Matinas BioPharma stock falls on strategic options (MTNB:NYSE) - Seeking Alpha
Nasdaq Down Over 200 Points; Microsoft Shares Fall After Q1 Results - Benzinga
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction - The Manila Times
Matinas BioPharma Announces the Termination of MAT2203 - GlobeNewswire
MTNB stock touches 52-week low at $2.87 amid market challenges By Investing.com - Investing.com South Africa
MTNB stock touches 52-week low at $2.87 amid market challenges - Investing.com India
Highbridge Capital Management's Strategic Acquisition in Matinas BioPharma - GuruFocus.com
MTNB stock touches 52-week low at $3.24 amid market challenges - Investing.com Australia
TMT Acquisition Corp Announces Changes to Contribution to Trust Account and the Use of Funds in Trust Account to Pay Dissolution Expenses in Connection with Extension Amendment Proposal - StockTitan
Mativ Holdings, Inc. Announces Pricing of Its $400 Million Offering of Senior Notes - Yahoo Finance
Checking in on Mattel, Inc. (MAT) after recent insiders movement - Knox Daily
TMT Acquisition Corp Announces Adjournment of Extraordinary General Meeting of Shareholders - StockTitan
68,521 Shares in Metals Acquisition Limited (NYSE:MTAL) Purchased by Rhumbline Advisers - Defense World
Mativ Holdings offers senior notes to finance existing debt - MSN
30 Shares in Mettler-Toledo International Inc. (NYSE:MTD) Acquired by Itau Unibanco Holding S.A. - Defense World
Clear Street LLC Reduces Holdings in TMT Acquisition Corp (NASDAQ:TMTC) - Defense World
Highbridge Capital Management LLC Takes $1.69 Million Position in Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) - Defense World
Stock Analysts’ Downgrades for September 18th (ATNM, BHR, CALX, FITB, MEDP, MMSI, MOH, MTRX, NPK, PRMW) - Defense World
Mattel price returns higherForecast today18-09-2024 - Economies.com
Rhumbline Advisers Sells 3,565 Shares of Mativ Holdings, Inc. (NYSE:MATV) - Defense World
Brothers of 18-year-old killed outside Nashville club speak out against gun violence - WKRN News 2
One person shot after multiple people were fighting at Nashville gas station - News Channel 5 Nashville
Mattr sells Brazilian pipe coating business for US$17.5 million | 2024-09-16 | Investing News - Stockhouse Publishing
Implant maker Tenon Medical nearly triples its market capitalization in two days - Kursiv Media
At least 3 dead after overnight shooting in Antioch - Yahoo! Voices
Tenon Medical stock jumps 73% in wake of Nasdaq listing update (NASDAQ:TNON) - Seeking Alpha
Stocks of the Hour: Locksley Resources, MTM Critical Metals, Battery Age Minerals - Finance News Network
Matinas BioPharma (NYSEAMERICAN:MTNB) Shares Gap Up to $3.64 - Defense World
Towercrest Capital Management Invests $299,000 in Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) - MarketBeat
Matinas BioPharma (NYSEAMERICAN:MTNB) Shares Gap Down to $3.72 - MarketBeat
Matinas BioPharma Holdings (FRA:6LJ0) Net Income : €-21.22 Mil (TTM As of Jun. 2024) - GuruFocus.com
Matinas BioPharma (NYSEAMERICAN:MTNB) Hits New 12-Month Low at $3.77 - MarketBeat
Matinas BioPharma implements reverse stock split By Investing.com - Investing.com Australia
Matinas BioPharma (NYSEAMERICAN:MTNB) Shares Up 4,230.1% - MarketBeat
Matinas BioPharma implements reverse stock split - Investing.com
Matinas BioPharma stock hits 52-week low at $4.49 - Investing.com
MATINAS BIOPH. NEW O.N. Trade Ideas — FWB:6LJ0 - TradingView
Matinas BioPharma stock hits 52-week low at $4.49 By Investing.com - Investing.com Canada
Matinas BioPharma (NYSEAMERICAN:MTNB) Hits New 1-Year High at $4.67 - MarketBeat
Matinas BioPharma enacts reverse stock split - Investing.com
MTNB’s Stock Market Expedition: Traversing Gains and Losses in 2023 - The InvestChronicle
An analyst sees good growth prospects for Matinas Biopharma Holdings Inc (MTNB) - SETE News
Balance Sheet Dive: Matinas Biopharma Holdings Inc (MTNB)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Should investors be concerned about Matinas Biopharma Holdings Inc (MTNB)? - US Post News
Does Matinas Biopharma Holdings Inc (MTNB) offer a good opportunity for investors? - SETE News
Matinas Biopharma Holdings Inc (MTNB) Stock: A Year of Market Fluctuations - The InvestChronicle
Financial Health Check: Examining Matinas Biopharma Holdings Inc (MTNB)’s Key Ratios - The Dwinnex
Matinas Biopharma Holdings Inc Stock (MTNB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):